Consensus $2.64. Lowers revenue view $720M-$760M from $760M-$800M, consensus $779.98M.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RGEN:
- Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
- RGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Repligen to Report First Quarter 2023 Financial Results
- Repligen initiated with a Buy at Benchmark
- Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum